INO Stock News: Inovio Pharmaceuticals Inc up on coronavirus vaccine hopes, competes with Novavax, Moderna

Inovio Pharmaceuticals is trading close to the highest since 2007 amid coronavirus vaccine hopes.
INO is competing with other efforts from Novavax and Moderna.
An upbeat market mood may carry it even higher.

Inovio Pharmaceuticals Inc (NASDAQ: INO) has kicked off the short trading week on a high note, trading closer to $15. The Pennsylvania-based pharma firm is focused on synthetic DNA products for cancer and also infectious diseases – which comes handy amid the global fight against COVID-19.

The reason for the recent rise stems from the company's report on promising results from preclinical studies for a coronavirus vaccine. The test of INO-480 in mice and guinea pigs is seen to have generated robust neutralizing antibodies and also T-cell responses to the SARS-Cov-2 virus. The company is working with the Witsatr institute, Public Health England, Fudan University, Advaccine, and the University of Texas in its efforts.

The news from INO competes with Novavax, another pharmaceutical that focuses on vaccines and has announced the beginning of a human trial. Earlier this month, markets were thrilled by Moderna's report of success with humans, but the lack of details about its immunization cast doubts

Inovio Pharmaceuticals Stock

The rise in INO's price seems relatively limited in comparison to its peers as competition is causing confusion among investors. Which firm will be the first to launch a vaccine? That remains an open question.

Another reason for the lack of a double-digit move – at least for now – is that the company is already worth $2.3 billion and its shares trade at double-digits in dollars. INO is a relatively mature company that has been around since 1979.

More, according to Elliott Wave Analysis theory, the stock price is close to completing a cycle:

After a wave ((5)) of Red I is complete, a lengthy multi month correction may take place in 3,7 or 11 swings before more upside is expected to resume.

Share: Feed news

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.

If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.

FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.

The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.